Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SOTIO a.s.
Use of vaccine to improve Prostate Specific Antigen (PSA) levels.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male 18 years and older
Histologically confirmed prostate adenocarcinoma
Presence of bone or soft tissue metastasis (by CT or PET or MRI and/or scintigraphy)
Androgen deprivation therapy using Luteinizing-hormone-releasing hormone ( LHRH) analogues commenced at least one month and at most three months prior randomization or orchiectomy performed at least one month and at most three months prior randomization
Serum testosterone level at screening (≤ 1.7 nmol/l, resp. ≤ 50 ng/dL)
Eastern Cooperative Oncology Group (ECOG) 0-2
You may not be if
Confirmed brain and/or leptomeningeal metastases
Prior or ongoing chemotherapy for prostate cancer
Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater
Other uncontrolled intercurrent illness
Treatment with immunotherapy against prostate cancer
Clinically significant cardiovascular disease
Active autoimmune disease requiring treatment
Clareo Health | Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
